首页 | 本学科首页   官方微博 | 高级检索  
     

重组腺病毒胸苷激酶基因构建体联合更昔洛韦治疗移植瘤裸鼠小细胞肺癌的实验研究
引用本文:Zhou JF,Chen G,Lu YP,Wang SX,Ma D. 重组腺病毒胸苷激酶基因构建体联合更昔洛韦治疗移植瘤裸鼠小细胞肺癌的实验研究[J]. 中华肿瘤杂志, 2004, 26(2): 68-70
作者姓名:Zhou JF  Chen G  Lu YP  Wang SX  Ma D
作者单位:430030,武汉,华中科技大学同济医学院附属同济医院肿瘤生物医学中心
基金项目:国家“十五”重大科技专项创新药物和中药现代化项目 ( 2 0 0 2AA2Z3 3 48)
摘    要:目的 观察以腺病毒为载体的单纯疱疹病毒胸苷激酶基因重组构建体 (ADV TK)联合更昔洛韦 (GCV)体内抗肺癌的活性。方法 建立移植瘤裸鼠小细胞肺癌模型 ,肺癌局部注射ADV TK后 ,腹腔注射GCV ,观察肿瘤体积、相对肿瘤体积、瘤重、相对肿瘤增殖率以及肿瘤体积生长变化的时间曲线 ,评价ADV TK的抗肿瘤活性。结果 在作用底物GCV存在条件下 ,ADV TK对人癌裸鼠移植性小细胞肺癌生长具有明显抑制作用 ,对裸鼠移植性小细胞肺癌的体积和瘤重的抑制效应与ADV TK呈剂量依赖性增强 ,且未达量效平台期 ,其中 6 .0× 10 9病毒颗粒 /kg剂量组的肿瘤生长抑制率分别达到 6 4 .6 %和 81.7%。将ADV TK和GCV分别单独应用 ,结果显示对肿瘤生长均有一定的抑制作用 ,但与阴性对照组相比 ,差异无显著性 (P >0 .0 5 )。结论 ADV TK联合GCV对肺癌具有明确的实验性治疗作用 ,值得进一步研究 ,开展临床试验。

关 键 词:重组腺病毒 胸苷激酶 基因构建体 更昔洛韦 治疗 移植瘤 裸鼠 小细胞肺癌 肿瘤

Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene transfer followed by ganiciclovir administration effectively inhibits growth of human small-cell lung cancer in a murine xenotransplant model
Zhou Jian-feng,Chen Gang,Lu Yun-ping,Wang Shi-xuan,Ma Ding. Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene transfer followed by ganiciclovir administration effectively inhibits growth of human small-cell lung cancer in a murine xenotransplant model[J]. Chinese Journal of Oncology, 2004, 26(2): 68-70
Authors:Zhou Jian-feng  Chen Gang  Lu Yun-ping  Wang Shi-xuan  Ma Ding
Affiliation:Biomedical Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Abstract:OBJECTIVE: Adenovirus vector-mediated herpes simplex virus thymidine kinase gene (ADV-TK) transfer in combination with ganiciclovir (GCV) is one of the major gene therapy strategies to eradicate tumor cells. This study was aimed at determining the in vivo anti-tumor efficacy of ADV-TK in combination with ganiciclovir (GCV). METHODS: A murine xenotransplant model of human small-cell lung cancer was established. ADV-TK was administrated by intra-tumoral injection followed by intraperitoneal administration of GCV. The anti-tumor efficacy was evaluated using index of tumor volume, relative tumor volume, tumor weight, relative tumor proliferative rate, and tumor growth curve. RESULTS: In the presence of GCV, ADV-TK effectively inhibited growth of human small-cell lung cancer in a dose-dependent fashion. An inhibition plateau was not observed within the current dosage range. ADV-TK at a dose of 6.0 x 10(9) viral particles/kg in the presence of GCV lead to 64.6% and 81.7% inhibition of tumor growth respectively in two independent experiments. ADV-TK or GCV alone caused slight inhibition of tumor growth, which was not statistically significant as compared to the negative control group (P > 0.05). CONCLUSION: ADV-TK followed by GCV is highly efficacious to inhibit the growth of human small-cell lung cancer in a murine xenotransplant model. The results presented here are encouraging to warrant a further clinical evaluation of the potential therapeutic benefits of this strategy.
Keywords:Adenovirus vector  Herpes simplex virus thymidine kinase gene  Gene therapy  Carcinoma  small cell lung
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号